false
Catalog
The Lead Episode 88:Ablation for Atrial Fibrillati ...
The Lead Episode 88 Speaker Information
The Lead Episode 88 Speaker Information
Back to course
Pdf Summary
The article under discussion focuses on the use of ablation as a treatment for atrial fibrillation (AF) in patients with rare pathogenic variants in cardiomyopathy and arrhythmia genes. It was presented by Dr. William H. Sauer from Brigham and Women's Hospital, accompanied by contributors Dr. Victor Nauffal and Dr. Ezim Ajufo. This discussion was centered on research published in "JACC: Clinical Electrophysiology."<br /><br />The study, authored by a multi-disciplinary team of experts including Majd A. El-Harasis, Zachary T. Yoneda, and others, aims to shed light on the efficacy and safety of using ablation in this specific subset of patients. With the complexity of underlying genetic mutations, these patients often face unique challenges in the management of atrial fibrillation.<br /><br />Ablation is a minimally invasive procedure that targets the areas of the heart responsible for AF by delivering energy to disrupt abnormal electrical circuits. However, the implications of applying this treatment to individuals with genetic predispositions linked to cardiomyopathy and arrhythmias necessitate a careful examination of risks and benefits.<br /><br />Dr. Sauer disclosed receiving honoraria and consulting fees from companies like Biotronik and Abbott, as well as conducting research with Medtronic. Dr. Ajufo and Dr. Nauffal reported no disclosures. The discussion emphasized not just the technical aspects of ablation, but also the broader implications for personalized medicine and tailored healthcare strategies for individuals with genetic variants affecting heart rhythm and structure.<br /><br />This collaborative exploration aims to refine treatment protocols and improve outcomes for this high-risk patient group, ensuring that interventions like ablation are both effective and aligned with the genetic contexts of affected individuals.
Keywords
ablation
atrial fibrillation
pathogenic variants
cardiomyopathy
arrhythmia genes
JACC: Clinical Electrophysiology
genetic predisposition
personalized medicine
treatment protocols
heart rhythm
Heart Rhythm Society
1325 G Street NW, Suite 500
Washington, DC 20005
P: 202-464-3400 F: 202-464-3401
E: questions@heartrhythm365.org
© Heart Rhythm Society
Privacy Policy
|
Cookie Declaration
|
Linking Policy
|
Patient Education Disclaimer
|
State Nonprofit Disclosures
|
FAQ
×
Please select your language
1
English